Quoin Pharmaceuticals (QNRX) Competitors

Allurion Technologies (NYSE:ALUR) and Quoin Pharmaceuticals (NASDAQ:QNRX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, earnings, institutional ownership, risk, media sentiment, dividends, analyst recommendations, community ranking and profitability.

Do analysts recommend ALUR or QNRX?

Allurion Technologies currently has a consensus target price of $22.83, suggesting a potential upside of 768.19%. Given Allurion Technologies' stronger consensus rating and higher probable upside, equities research analysts clearly believe Allurion Technologies is more favorable than Quoin Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Allurion Technologies	0 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	3.00
Quoin Pharmaceuticals	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00

Does the media refer more to ALUR or QNRX?

In the previous week, Quoin Pharmaceuticals had 1 more articles in the media than Allurion Technologies. MarketBeat recorded 2 mentions for Quoin Pharmaceuticals and 1 mentions for Allurion Technologies. Quoin Pharmaceuticals' average media sentiment score of 1.43 beat Allurion Technologies' score of 1.00 indicating that Quoin Pharmaceuticals is being referred to more favorably in the news media.

Company	Overall Sentiment
Allurion Technologies	Positive
Quoin Pharmaceuticals	Positive

Is ALUR or QNRX more profitable?

Quoin Pharmaceuticals has a net margin of 0.00% compared to Allurion Technologies' net margin of -71.24%. Allurion Technologies' return on equity of 0.00% beat Quoin Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Allurion Technologies	-71.24%	N/A	-56.75%
Quoin Pharmaceuticals	N/A	-125.60%	-64.77%

Do institutionals & insiders hold more shares of ALUR or QNRX?

21.4% of Allurion Technologies shares are held by institutional investors. Comparatively, 8.6% of Quoin Pharmaceuticals shares are held by institutional investors. 22.4% of Allurion Technologies shares are held by company insiders. Comparatively, 3.7% of Quoin Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Which has stronger valuation & earnings, ALUR or QNRX?

Quoin Pharmaceuticals has lower revenue, but higher earnings than Allurion Technologies. Allurion Technologies is trading at a lower price-to-earnings ratio than Quoin Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Allurion Technologies	$28.30M	0.69	-$80.61M	-$12.50	-0.21
Quoin Pharmaceuticals	N/A	N/A	-$8.69M	-$48.81	-0.17

Does the MarketBeat Community prefer ALUR or QNRX?

Allurion Technologies received 3 more outperform votes than Quoin Pharmaceuticals when rated by MarketBeat users. Likewise, 66.67% of users gave Allurion Technologies an outperform vote while only 55.56% of users gave Quoin Pharmaceuticals an outperform vote.

Company	Underperform	Outperform
Allurion Technologies	Outperform Votes 8 66.67%	Underperform Votes 4 33.33%
Quoin Pharmaceuticals	Outperform Votes 5 55.56%	Underperform Votes 4 44.44%

Which has more volatility and risk, ALUR or QNRX?

Allurion Technologies has a beta of -0.47, suggesting that its stock price is 147% less volatile than the S&P 500. Comparatively, Quoin Pharmaceuticals has a beta of 1.44, suggesting that its stock price is 44% more volatile than the S&P 500.

Summary

Allurion Technologies beats Quoin Pharmaceuticals on 13 of the 18 factors compared between the two stocks.